Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Brainstorm Cell (BCLI)

Brainstorm Cell (BCLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,445
  • Shares Outstanding, K 36,486
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,460 K
  • 60-Month Beta 0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.51
Trade BCLI with:

Options Overview Details

View History
  • Implied Volatility 188.40% ( +80.06%)
  • Historical Volatility 56.23%
  • IV Percentile 99%
  • IV Rank 84.45%
  • IV High 209.88% on 05/16/22
  • IV Low 71.75% on 04/29/22
  • Put/Call Vol Ratio 10.07
  • Today's Volume 155
  • Volume Avg (30-Day) 144
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 20,788
  • Open Int (30-Day) 19,602

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.65 +9.06%
on 05/13/22
3.33 -13.21%
on 05/05/22
-0.18 (-5.86%)
since 04/20/22
3-Month
2.65 +9.06%
on 05/13/22
3.64 -20.60%
on 04/07/22
-0.30 (-9.40%)
since 02/18/22
52-Week
2.65 +9.06%
on 05/13/22
4.46 -35.20%
on 12/30/21
-0.60 (-17.19%)
since 05/20/21

Most Recent Stories

More News
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases

Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been...

MSB.AX : 0.990 (-1.49%)
LGVN : 8.19 (+0.37%)
ATHX : 0.2606 (-65.54%)
BCLI : 2.89 (-3.02%)
MESO : 3.51 (-1.96%)
BCDA : 1.6300 (+3.16%)
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the...

BCLI : 2.89 (-3.02%)
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...

BCLI : 2.89 (-3.02%)
Tenax Therapeutics, Inc. Expands Board of Directors

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today...

TENX : 0.6360 (-6.44%)
RDHL : 1.0300 (-1.90%)
BCLI : 2.89 (-3.02%)
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased...

BCLI : 2.89 (-3.02%)
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI)....

BCLI : 2.89 (-3.02%)
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®

SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs,...

CTLT : 100.19 (+0.46%)
BCLI : 2.89 (-3.02%)
BrainStorm to Present at Scientific Conferences in September

Advanced Therapies & Expo 2020 on September 9

BCLI : 2.89 (-3.02%)
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs

Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4

BCLI : 2.89 (-3.02%)
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS

Intratracheal administration of exosomes extracted from MSC’s using NurOwn ® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model

BCLI : 2.89 (-3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

See More

Key Turning Points

3rd Resistance Point 3.11
2nd Resistance Point 3.06
1st Resistance Point 2.98
Last Price 2.89
1st Support Level 2.85
2nd Support Level 2.80
3rd Support Level 2.72

See More

52-Week High 4.46
Fibonacci 61.8% 3.77
Fibonacci 50% 3.56
Fibonacci 38.2% 3.34
Last Price 2.89
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar